STOCK TITAN
  1. Home
  2. Sec-filings
  3. NRXP
  4. [8-K] NRX Pharmaceuticals, Inc. Reports Material Event

NRx Pharmaceuticals (NASDAQ: NRXP) details FDA review of ketamine ANDA

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

NRx Pharmaceuticals is updating investors on U.S. FDA review of its Abbreviated New Drug Application (ANDA) for preservative‑free ketamine. On July 30, 2026 the FDA reported no major deficiencies related to the drug components, but requested a label update to match the reference drug Ketalar and identified a single major deficiency concerning the twist‑off cap of the luer lock vial, which affects the container closure.

NRx highlighted performance testing on 3,500 vials from seven manufacturing batches and real‑world experience with 11.9 million doses of similar products using the same vial design, without complaints, returns, or recalls. After an August 6, 2026 clarification meeting, the FDA asked for formal manufacturer certifications that this product is made on the same lines and with the same materials as three approved ANDA products, then agreed to immediately reinitiate review focused on this packaging issue and to complete it in the shortest‑possible review cycle. Management notes ketamine’s presence on the FDA drug shortage list and expresses optimism about resolving the packaging concern and achieving initial commercial sales in 2026, while acknowledging that regulatory outcomes cannot be assured.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Doses shipped using same vial design 11.9 million doses Past 12 months for three previously approved ANDA products
Vials tested in ANDA submission 3,500 vials Randomly selected from first 7 manufacturing batches
Previously-approved ANDA products using vial 3 products Luer lock vial already used in three approved ANDA products
Manufacturing batches in testing sample 7 batches First 7 manufacturing batches used for vial performance testing
Estimated first-round ANDA approval rate 14% - 18% Management’s cited estimate for ANDAs achieving first-round approval
Abbreviated New Drug Application regulatory
"NRx Pharmaceuticals Inc. filed an Abbreviated New Drug Application"
An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.
Reference Listed Drug regulatory
"reflect a labeling change filed by the manufacturer of the Reference Listed Drug"
A reference listed drug is the approved, original version of a medicine that regulators use as the official “master copy” when evaluating generic versions for safety, strength and how the body absorbs it. For investors, the RLD determines what competitors must match to win approval, shaping how quickly lower‑priced generics can enter the market and therefore affecting future sales, pricing pressure and legal disputes over market exclusivity.
luer lock vial technical
"major deficiency related to the twist-off cap of the product’s luer lock vial"
Office of Generic Drugs regulatory
"The meeting was attended both by leadership of the Office of Generic Drugs"
Office of Generic Drugs is the regulatory unit that reviews and approves generic versions of prescription medicines, ensuring they match brand-name drugs in safety, strength, quality and performance. Think of it as a quality-control office that decides when cheaper, interchangeable copies can enter the market; its decisions affect competition, drug pricing and revenue prospects for both brand and generic drugmakers, so investors watch its approvals and guidance closely.
Center for Drug Evaluation and Research regulatory
"Senior Leadership of the FDA Center for Drug Evaluation and Research (CDER)"
A U.S. federal regulatory office that reviews and decides whether new and existing prescription and over‑the‑counter drugs are safe and effective for patients. Its decisions set the rules for whether a medicine can be sold, what claims can be made about it, and what warnings are required. Investors watch it like a gatekeeper: approval unlocks market access and revenue, while delays or rejections create risk and uncertainty for a drug maker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did the FDA tell NRx Pharmaceuticals (NRXP) about its preservative-free ketamine ANDA?
The FDA’s first-round review found no major deficiencies related to the drug components of NRx’s preservative-free ketamine ANDA, but requested a label update and identified one major packaging-related deficiency involving the luer lock vial’s twist-off cap.

What is the single major deficiency the FDA identified for NRXP’s ketamine product?
The FDA highlighted a major deficiency related to the twist-off cap of the luer lock vial, concerned the vial tip could deform in clinical use. Because this affects the container closure, it is classified as a major issue, and the FDA requested further supporting information.

What supporting data has NRx Pharmaceuticals (NRXP) provided on the vial design?
NRx cited experience with 11.9 million doses of three previously approved ANDA products using the same luer lock vial and testing of 3,500 vials from seven batches, reporting no observed defects, complaints, returns, or recalls, plus independent torque verification data.

How will the FDA proceed with review of NRXP’s preservative-free ketamine ANDA?
After an August 6, 2026 meeting, the FDA requested manufacturer certifications on manufacturing lines and materials, then committed to immediately reinitiate review of the ANDA and to complete it in the shortest-possible review cycle, focusing on the packaging issue.

What are NRx Pharmaceuticals’ (NRXP) expectations for ketamine commercialization timing?
Management is optimistic that resolving the packaging concern could allow first commercial sales of preservative-free ketamine in 2026, citing ketamine’s presence on the FDA drug shortage list, while emphasizing that regulatory determinations and timelines cannot be guaranteed.

How does NRx view its first-round ANDA review outcome relative to industry experience?
NRx notes its first-round review showed no drug-related major deficiencies and views this positively, referencing estimates that only about 14%–18% of ANDAs achieve approval on first-round review, though its own ANDA has not yet received final approval.
false 0001719406 0001719406 2026-08-07 2026-08-07
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 7, 2026
 
 
NRX PHARMACEUTICALS, INC.
  
 
(Exact name of registrant as specified in its charter)
  
 
 
Delaware
  
001-38302
  
82-2844431
  
 
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification Number)
  
 
 
1201 Orange Street, Suite 600
Wilmington, Delaware
 
19801
  
 
(Address of principal executive offices)
  
(Zip Code) 
  
 
(484)254-6134
(Registrant’s telephone number, including area code) 
 
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.424)
   
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: 
 
Title of each class
  
Trading Symbol
  
Name of exchange on which registered
         
Common Stock, par value $0.001 per share
  
NRXP
  
The Nasdaq Stock Market LLC
         
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 7.01 Regulation FD Disclosure.
 
As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination on first-round review that there were no major deficiencies related to the drug components of the product. The FDA did ask the company to update the label of the product to reflect a labeling change filed by the manufacturer of the Reference Listed Drug (Ketalar®) and identified a major deficiency related to the twist-off cap of the product’s luer lock vial, where an FDA reviewer expressed concern that the vial tip had the potential to deform in clinical use. The FDA sought confirmation that this could not pose a risk to patient safety. The classification as major is required because the matter affects the container closure.
 
Management advised the FDA that the luer lock vial has been used in three previously-approved ANDA products and 11.9 million doses of those products have been shipped in the past 12 months without complaints, returns, or recalls. The ANDA contained testing information on 3,500 vials randomly selected from the first 7 manufacturing batches in which the proper function of the luer lock tip was assessed and no defects were observed in any tested vial. The Company additionally provided verification data from an independent reference laboratory documenting that the torque (measured in Newton-Centimeters) required to open the vial was within the design specifications of the product and the three currently-approved ANDA products.
 
The FDA granted the Company a clarification meeting that was held on August 6, 2026 to identify the exact information that the Company will be required to provide to address the FDA’s concern about the proper function of the luer lock vial tip. The FDA requested that the company submit certifications from its manufacturer that the preservative-free ketamine ANDA product is manufactured on the same manufacturing lines with the same machinery, plastics, and other characteristics as the three approved ANDA products already in commercial distribution. This information was included in the ANDA as submitted and will now be supplied to the FDA as signed certifications from the Company’s manufacturers.
 
Based on the meeting, the FDA committed to immediately reinitiate review of the ANDA in order to resolve this single identified major deficiency and committed to completing the review in the shortest-possible review cycle. The meeting was attended both by leadership of the Office of Generic Drugs and by Senior Leadership of the FDA Center for Drug Evaluation and Research (CDER). FDA recognized that ketamine is a strategic drug that appears on the current FDA drug shortage list.
 
NRx management views the completion of a first-round ANDA review with no drug-related major deficiencies as a positive outcome, given that only 14% - 18% of ANDAs are estimated to achieve approval on first-round review. Although no assurances can be given on regulatory determinations, management is optimistic that the identified concern related to packaging will be resolved in a timely manner, consistent with first commercial sales in 2026, given that FDA has recognized the current drug shortage and lack of U.S.-based supply of ketamine and has committed to completing the review in the shortest possible review time frame. HHS leadership has identified ketamine as a strategic drug, as have other agencies and departments of the Federal Government.
 
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may include, among other things, statements regarding the Company’s financial outlook, product development activities, regulatory matters, business prospects, market and industry trends and conditions, and the Company’s strategies, plans, objectives and goals.
 
Forward-looking statements are based on the current beliefs, expectations, estimates, forecasts and projections of, and assumptions made by and information currently available to, the Company’s management. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goal,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “would,” “seek,” “plan,” “intend” and similar expressions, or the negative of such terms, are intended to identify forward-looking statements.
 
Forward-looking statements are subject to significant risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the Company’s limited operating history; its ability to obtain regulatory approval for, develop, manufacture and commercialize its product candidates; the timing and results of regulatory submissions, reviews and decisions; manufacturing difficulties or delays; competition and technological developments; changes in applicable laws and regulations; the Company’s ability to protect and enforce its intellectual property rights; its ability to retain key personnel, manage growth and obtain additional financing; general economic, market and industry conditions; and the risks described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. There can be no assurance that any product candidate will receive the necessary regulatory approvals or, if approved, will be commercially successful.
 
Forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NRx Pharmaceuticals, Inc.
  
       
Date: August 7, 2026
By:
/s/ Jonathan Javitt
  
 
Name:
Jonathan Javitt
  
 
Its:
Chief Executive Officer
  
 
 
 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents